This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Willberg, C. B.
Right arrow Articles by Nixon, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Willberg, C. B.
Right arrow Articles by Nixon, D. F.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, June 2007, p. 785-788, Vol. 14, No. 6
1071-412X/07/$08.00+0     doi:10.1128/CVI.00048-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Rational Peptide Selection To Detect Human Immunodeficiency Virus Type 1-Specific T-Cell Responses under Resource-Limited Conditions{triangledown}

C. B. Willberg,1 S. K. Pillai,2 E. R. Sharp,1 M. G. Rosenberg,3 J. D. Agudelo,1 J. D. Barbour,4 and D. F. Nixon1*

Division of Experimental Medicine, Department of Medicine, UCSF, San Francisco, California 94158,1 Veterans Affairs Medical Center, San Francisco, California 94121,2 Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461,3 Positive Health Program, San Francisco General Hospital, UCSF, San Francisco, California 941434

Received 23 January 2007/ Returned for modification 16 February 2007/ Accepted 21 March 2007

Understanding human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses is important for the development of vaccines and therapies. We describe a novel method for the rational selection of peptides that target stable regions of the HIV-1 genome, rich in epitopes specifically recognized by the study population. This method will be of particular use under resource/sample-limited conditions.

* Corresponding author. Mailing address: Division of Experimental Medicine, Department of Medicine, UCSF, San Francisco, CA 94158. Phone: (415) 206-5518. Fax: (415) 206-5581. E-mail: douglas.nixon{at}ucsf.edu

{triangledown} Published ahead of print on 4 April 2007.

Clinical and Vaccine Immunology, June 2007, p. 785-788, Vol. 14, No. 6
1071-412X/07/$08.00+0     doi:10.1128/CVI.00048-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»